Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer.

Xi, Yue; Li, Ting; Xi, Yun; Zeng, Xinyi; Miao, Ying; Guo, Rui; Zhang, Min; Li, Biao

Xi, Yue; Li, Ting; Xi, Yun; Zeng, Xinyi; Miao, Ying; Guo, Rui; Zhang, Min; Li, Biao.

Afiliação

Xi Y; Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025, China.
Li T; Collaboration Innovation Center for Molecular Imaging of Precision Medicine, Ruijin Center, Shanghai, 200025, China.
Xi Y; Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025, China.
Zeng X; Collaboration Innovation Center for Molecular Imaging of Precision Medicine, Ruijin Center, Shanghai, 200025, China.
Miao Y; Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025, China.
Guo R; Collaboration Innovation Center for Molecular Imaging of Precision Medicine, Ruijin Center, Shanghai, 200025, China.
Zhang M; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li B; Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025, China.

Cancer Cell Int ; 22(1): 271, 2022 Sep 01.

Article em En | MEDLINE | ID: mdl-36050724

Palavras-chave

Combination therapy; Gemcitabine resistance; Triple-negative breast cancer; hENT1; miR-143

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Cell Int Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google